 The results of this systematic review suggest that Infliximab may be the most effective treatment for intravenous immunoglobulin, IVIG, resistant Kawasaki disease, KD, followed by a second IVIG infusion and intravenous pulse methylprednisolone, IVMP. Infliximab was found to be associated with fewer adverse events than the other two treatments, but it also had a higher rate of hepatomegaly. The second IVIG infusion was associated with a greater risk of hemolytic anemia, while IVMP was associated with a greater risk of bradycardia, hyperglycemia, hypertension, and hypothermia. There was no significant difference between the three treatments in terms of the risk of developing a coronary artery aneurysm, CAA. This article was authored by Yen Pan, Chi Hong Fan, and Luoyi Hu.